Clinical Trial Update: Immunogenicity of 3+1 Versus 2+1 Schedule for PCV7 [Phase 4]

View source ↗

Summary

Phase 4 trial comparing 3+1 vs 2+1 dosing schedules for the pneumococcal conjugate vaccine PCV7. The study reports on immunogenicity outcomes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease

Drugs mentioned

• PCV7 (pneumococcal conjugate vaccine 7-valent)

Snippet

Sponsor: The University of Hong Kong | Conditions: Infectious Disease | Phase 4 | Status: COMPLETED